The Claim
Combination therapy with photodynamic therapy and anti-VEGF agents reduces the number of anti-VEGF injections required by treatment-naïve patients with polypoidal choroidal vasculopathy compared to anti-VEGF monotherapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For patients with polypoidal choroidal vasculopathy who have not received prior treatment, combining photodynamic therapy with anti-VEGF injections results in fewer anti-VEGF injections over time than using anti-VEGF injections alone, without reducing treatment effectiveness.
See the scientific wording
Combination therapy with photodynamic therapy and anti-VEGF agents reduces the number of anti-VEGF injections required by treatment-naïve patients with polypoidal choroidal vasculopathy compared to anti-VEGF monotherapy, indicating a lower treatment burden without compromising efficacy.
The light treatment damages abnormal blood vessels in the eye, making them less leaky and more stable. This reduces the need for ongoing injections that block a protein causing vessel leakage and growth.
What the research says
1 studyWhen doctors combine a special light treatment (PDT) with eye injections for a type of eye disease, patients need fewer injections over time—and their vision still gets better. This means less hassle and fewer trips to the doctor.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.